**The primary drivers of trader sentiment on full marijuana rescheduling to Schedule III center on the expedited DEA administrative process initiated after President Trump’s December 2025 executive order.** In April 2026, the DOJ and DEA immediately moved FDA-approved products and state-licensed medical marijuana to Schedule III while launching a new hearing specifically for broader rescheduling of all cannabis. That hearing ran from June 29 to July 15, 2026, with DEA counsel presenting evidence in support of the change; post-hearing briefs are due August 17, 2026, after which the administrative law judge will issue a recommended decision. Subsequent steps include review by the DEA Administrator, possible public comment or appeals, and publication of a final rule. Traders are weighing the compressed timeline and government advocacy in the record against the remaining procedural stages, any litigation risks, and historical precedent for how long similar Controlled Substances Act rulemakings have taken once hearings conclude. No further major milestones are scheduled before the briefs deadline.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui$796,329 Vol.
Mar 31, 2026
September 30
14%
December 31
28%
$796,329 Vol.
September 30
$0 Vol.
14%
December 31
$186,758 Vol.
28%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The primary drivers of trader sentiment on full marijuana rescheduling to Schedule III center on the expedited DEA administrative process initiated after President Trump’s December 2025 executive order.** In April 2026, the DOJ and DEA immediately moved FDA-approved products and state-licensed medical marijuana to Schedule III while launching a new hearing specifically for broader rescheduling of all cannabis. That hearing ran from June 29 to July 15, 2026, with DEA counsel presenting evidence in support of the change; post-hearing briefs are due August 17, 2026, after which the administrative law judge will issue a recommended decision.
Subsequent steps include review by the DEA Administrator, possible public comment or appeals, and publication of a final rule. Traders are weighing the compressed timeline and government advocacy in the record against the remaining procedural stages, any litigation risks, and historical precedent for how long similar Controlled Substances Act rulemakings have taken once hearings conclude. No further major milestones are scheduled before the briefs deadline.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Pasar Dibuka: Feb 7, 2026, 5:04 PM ET
Volume
$796,329Tanggal Berakhir
Mar 31, 2026Pasar Dibuka
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The primary drivers of trader sentiment on full marijuana rescheduling to Schedule III center on the expedited DEA administrative process initiated after President Trump’s December 2025 executive order.** In April 2026, the DOJ and DEA immediately moved FDA-approved products and state-licensed medical marijuana to Schedule III while launching a new hearing specifically for broader rescheduling of all cannabis. That hearing ran from June 29 to July 15, 2026, with DEA counsel presenting evidence in support of the change; post-hearing briefs are due August 17, 2026, after which the administrative law judge will issue a recommended decision.
Subsequent steps include review by the DEA Administrator, possible public comment or appeals, and publication of a final rule. Traders are weighing the compressed timeline and government advocacy in the record against the remaining procedural stages, any litigation risks, and historical precedent for how long similar Controlled Substances Act rulemakings have taken once hearings conclude. No further major milestones are scheduled before the briefs deadline.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$796,329Tanggal Berakhir
Mar 31, 2026Pasar Dibuka
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**The primary drivers of trader sentiment on full marijuana rescheduling to Schedule III center on the expedited DEA administrative process initiated after President Trump’s December 2025 executive order.** In April 2026, the DOJ and DEA immediately moved FDA-approved products and state-licensed medical marijuana to Schedule III while launching a new hearing specifically for broader rescheduling of all cannabis. That hearing ran from June 29 to July 15, 2026, with DEA counsel presenting evidence in support of the change; post-hearing briefs are due August 17, 2026, after which the administrative law judge will issue a recommended decision. Subsequent steps include review by the DEA Administrator, possible public comment or appeals, and publication of a final rule. Traders are weighing the compressed timeline and government advocacy in the record against the remaining procedural stages, any litigation risks, and historical precedent for how long similar Controlled Substances Act rulemakings have taken once hearings conclude. No further major milestones are scheduled before the briefs deadline.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui
Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan